

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<b>BRAIN-D 3 of 13</b>  External request: Submission from Amgen, requesting consideration of the addition of bevacizumab-awwb as an appropriate substitute to bevacizumab for patients with recurrent glioblastoma.	Based upon review of the data, the panel consensus supported the addition of bevacizumab-awwb as a substitute for bevacizumab monotherapy for patients with recurrent glioblastoma. The following footnote was added for bevacizumab monotherapy: An FDA-approved biosimilar is an appropriate substitute for bevacizumab. <ul style="list-style-type: none"> <li>Prescribing information for bevacizumab-awwb: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761028s004lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761028s004lbl.pdf</a></li> <li>See Submission for references.</li> </ul>	15	0	1	12